BiomX Inc. (PHGE): Price and Financial Metrics

BiomX Inc. (PHGE): $0.35

0.01 (-1.71%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add PHGE to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#NR of NR

in industry

PHGE Price/Volume Stats

Current price $0.35 52-week high $0.86
Prev. close $0.36 52-week low $0.19
Day low $0.35 Volume 3,000
Day high $0.35 Avg. volume 2,671,990
50-day MA $0.28 Dividend yield N/A
200-day MA $0.33 Market Cap 16.09M

PHGE Stock Price Chart Interactive Chart >


BiomX Inc. (PHGE) Company Bio


BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.


PHGE Latest News Stream


Event/Time News Detail
Loading, please wait...

PHGE Latest Social Stream


Loading social stream, please wait...

View Full PHGE Social Stream

Latest PHGE News From Around the Web

Below are the latest news stories about BIOMX INC that investors may wish to consider to help them evaluate PHGE as an investment opportunity.

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced it will host a virtual KOL Event on December 4, 2023 at 12:00 PM ET to discuss the positive topline results recently announced from Part 2 of Phase 1b/2a trial of BX004 in cystic fibrosis (CF) patients with chronic Pseudomonas

Yahoo | November 30, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning!

William White on InvestorPlace | November 29, 2023

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

BX004 showed clinically meaningful improvement in pulmonary function as measured in FEV11 and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain in a predefined subgroup of patients with reduced lung function2 Treatment with BX004 also achieved P. aeruginosa culture conversion to negative at end of 10 days of treatment in 3 patients (14%) versus none for placebo3 In a prespecified subgroup of patients on background use of continuous inhaled antibiotics, BX004 showed a 2.8 log10 CFU

Yahoo | November 29, 2023

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month BX004 received FDA Fast Track designation in August Part 1 data recently presented at the North American Cystic Fibrosis Conference (NACFC) CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific p

Yahoo | November 14, 2023

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in people with

Yahoo | October 27, 2023

Read More 'PHGE' Stories Here

PHGE Price Returns

1-mo 57.30%
3-mo 25.00%
6-mo -0.57%
1-year 9.37%
3-year -95.01%
5-year N/A
YTD 25.00%
2023 49.97%
2022 -88.33%
2021 -74.92%
2020 -34.12%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!